The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00129766




Registration number
NCT00129766
Ethics application status
Date submitted
10/08/2005
Date registered
12/08/2005
Date last updated
28/08/2013

Titles & IDs
Public title
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Scientific title
A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children
Secondary ID [1] 0 0
MI-CP110
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - motavizumab (MEDI-524)
Other interventions - palivizumab

Active Comparator: palivizumab - 15 mg/kg administered intramuscularly for 5 monthly doses

Experimental: motavizumab (MEDI-524) - 15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses


Other interventions: motavizumab (MEDI-524)
Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses

Other interventions: palivizumab
Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of RSV Hospitalization (Includes Deaths by RSV)
Timepoint [1] 0 0
Days 0 - 150
Primary outcome [2] 0 0
Number of Participants Reporting Any Adverse Events (AEs)
Timepoint [2] 0 0
Days 0 - 150
Primary outcome [3] 0 0
Number of Participants Reporting Any Related AEs
Timepoint [3] 0 0
Days 0 - 150
Primary outcome [4] 0 0
Number of Participants Reporting Any Serious Adverse Events (SAEs)
Timepoint [4] 0 0
Days 0 - 150
Primary outcome [5] 0 0
Number of Participants Reporting Any Related SAEs
Timepoint [5] 0 0
Days 0 - 150
Primary outcome [6] 0 0
Number of Participants Reporting AEs by Highest Severity Grade
Timepoint [6] 0 0
Days 0 - 150
Primary outcome [7] 0 0
Number of Participants Who Discontinued Study Drug Due to AEs
Timepoint [7] 0 0
Days 0 - 150
Primary outcome [8] 0 0
Number of Participants Who Died
Timepoint [8] 0 0
Days 0 - 150
Primary outcome [9] 0 0
Number of Participants Reporting Changes in Vital Signs From Baseline
Timepoint [9] 0 0
Days 0 - 150
Secondary outcome [1] 0 0
The Incidence of Outpatient Medically-attended Lower Respiratory Illness (LRI)
Timepoint [1] 0 0
Day 0 - 150
Secondary outcome [2] 0 0
The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups
Timepoint [2] 0 0
Days 0 - 150
Secondary outcome [3] 0 0
The Incidence of Medically-attended Otitis Media (OM) Infections
Timepoint [3] 0 0
Days 0 - 150
Secondary outcome [4] 0 0
The Frequency of Prescribed Antibiotics for Medically-attended LRI
Timepoint [4] 0 0
Days 0 - 150
Secondary outcome [5] 0 0
The Frequency of Prescribed Antibiotics for Medically-attended OM Infections
Timepoint [5] 0 0
Days 0 - 150
Secondary outcome [6] 0 0
The Number of Participants With Anti-motavizumab Antibodies
Timepoint [6] 0 0
Day 0 - 120
Secondary outcome [7] 0 0
The Serum Concentrations of Motavizumab at Day 0
Timepoint [7] 0 0
Day 0
Secondary outcome [8] 0 0
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 1
Timepoint [8] 0 0
30 days post Dose 1
Secondary outcome [9] 0 0
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 2
Timepoint [9] 0 0
30 days post Dose 2
Secondary outcome [10] 0 0
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 3
Timepoint [10] 0 0
30 days post Dose 3
Secondary outcome [11] 0 0
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 4
Timepoint [11] 0 0
30 days post Dose 4

Eligibility
Key inclusion criteria
- 24 months of age or younger at randomization (child must be randomized on or before
his/her 24-month birthday) with a diagnosis of chronic lung disease (CLD) of
prematurity requiring medical intervention/management (i.e., supplemental oxygen,
bronchodilators, or diuretics) within 6 months before randomization

OR:

- 35 weeks gestational age or less at birth and 6 months of age or younger at
randomization (children were to be randomized on or before his/her 6-month birthday)
Minimum age
No limit
Maximum age
24 Months
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Hospitalization at the time of randomization (unless discharge was anticipated within
10 days)

- Mechanical ventilation or other mechanical support (including continuous positive
airways pressure [CPAP])

- Life expectancy < 6 months

- Active RSV infection (a child with signs/symptoms of respiratory infection must have
had negative RSV testing)

- Known renal impairment

- Known hepatic dysfunction

- Chronic seizure or evolving or unstable neurologic disorder

- Congenital heart disease [CHD] (children with uncomplicated CHD [e.g., patent ductus
arterious (PDA), small septal defect] and children with complicated CHD that were
currently anatomically and hemodynamically normal could be enrolled)

- Known immunodeficiency

- Mother with HIV infection (unless the child has been proven to be not infected)

- Known allergy to Ig products

- Receipt of palivizumab, RSV-IGIV, or other RSV-specific monoclonal antibody, or any
other polyclonal antibody (for example, hepatitis B IG, IVIG, VZIG) within 3 months
prior to randomization

- Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)

- Previous receipt of RSV vaccines

- Participation in other investigational drug product studies

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,TAS,VIC,WA
Recruitment hospital [1] 0 0
The Canberra Hospital - Garran
Recruitment hospital [2] 0 0
John Hunter Children's Hospital - New Lambton
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Royal Children's Hospital (Brisbane) - Herston
Recruitment hospital [5] 0 0
Peninsula Clinical Research Centre - Kippa-Ring
Recruitment hospital [6] 0 0
Mater Mothers Hospital Raymond Terrace - South Brisbane
Recruitment hospital [7] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [8] 0 0
Royal Children's Hospital (Melbourne) - Parkville
Recruitment hospital [9] 0 0
Princess Margaret Children's Hospital - Subiaco
Recruitment hospital [10] 0 0
Women's and Children's Hospital - North Adelaide
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2305 - New Lambton
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
4021 - Kippa-Ring
Recruitment postcode(s) [6] 0 0
4101 - South Brisbane
Recruitment postcode(s) [7] 0 0
7000 - Hobart
Recruitment postcode(s) [8] 0 0
3052 - Parkville
Recruitment postcode(s) [9] 0 0
6008 - Subiaco
Recruitment postcode(s) [10] 0 0
5006 - North Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Delaware
Country [8] 0 0
United States of America
State/province [8] 0 0
District of Columbia
Country [9] 0 0
United States of America
State/province [9] 0 0
Florida
Country [10] 0 0
United States of America
State/province [10] 0 0
Georgia
Country [11] 0 0
United States of America
State/province [11] 0 0
Hawaii
Country [12] 0 0
United States of America
State/province [12] 0 0
Illinois
Country [13] 0 0
United States of America
State/province [13] 0 0
Indiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Kentucky
Country [15] 0 0
United States of America
State/province [15] 0 0
Louisiana
Country [16] 0 0
United States of America
State/province [16] 0 0
Maryland
Country [17] 0 0
United States of America
State/province [17] 0 0
Massachusetts
Country [18] 0 0
United States of America
State/province [18] 0 0
Michigan
Country [19] 0 0
United States of America
State/province [19] 0 0
Minnesota
Country [20] 0 0
United States of America
State/province [20] 0 0
Missouri
Country [21] 0 0
United States of America
State/province [21] 0 0
Nebraska
Country [22] 0 0
United States of America
State/province [22] 0 0
Nevada
Country [23] 0 0
United States of America
State/province [23] 0 0
New Hampshire
Country [24] 0 0
United States of America
State/province [24] 0 0
New Jersey
Country [25] 0 0
United States of America
State/province [25] 0 0
New York
Country [26] 0 0
United States of America
State/province [26] 0 0
North Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oklahoma
Country [29] 0 0
United States of America
State/province [29] 0 0
Oregon
Country [30] 0 0
United States of America
State/province [30] 0 0
Pennsylvania
Country [31] 0 0
United States of America
State/province [31] 0 0
Rhode Island
Country [32] 0 0
United States of America
State/province [32] 0 0
South Carolina
Country [33] 0 0
United States of America
State/province [33] 0 0
South Dakota
Country [34] 0 0
United States of America
State/province [34] 0 0
Tennessee
Country [35] 0 0
United States of America
State/province [35] 0 0
Texas
Country [36] 0 0
United States of America
State/province [36] 0 0
Utah
Country [37] 0 0
United States of America
State/province [37] 0 0
Virginia
Country [38] 0 0
United States of America
State/province [38] 0 0
West Virginia
Country [39] 0 0
United States of America
State/province [39] 0 0
Wisconsin
Country [40] 0 0
Argentina
State/province [40] 0 0
Buenos Aires
Country [41] 0 0
Argentina
State/province [41] 0 0
Capital Federal
Country [42] 0 0
Argentina
State/province [42] 0 0
Cordoba
Country [43] 0 0
Austria
State/province [43] 0 0
Graz
Country [44] 0 0
Austria
State/province [44] 0 0
Tulln
Country [45] 0 0
Austria
State/province [45] 0 0
Wien
Country [46] 0 0
Brazil
State/province [46] 0 0
Campinas
Country [47] 0 0
Brazil
State/province [47] 0 0
Curitiba
Country [48] 0 0
Brazil
State/province [48] 0 0
Porto Alegre
Country [49] 0 0
Brazil
State/province [49] 0 0
Ribeirao Preto
Country [50] 0 0
Brazil
State/province [50] 0 0
Sao Paulo
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Pleven
Country [52] 0 0
Bulgaria
State/province [52] 0 0
Plovdiv
Country [53] 0 0
Bulgaria
State/province [53] 0 0
Rousse
Country [54] 0 0
Bulgaria
State/province [54] 0 0
Sofia
Country [55] 0 0
Bulgaria
State/province [55] 0 0
Varna
Country [56] 0 0
Canada
State/province [56] 0 0
Calgary
Country [57] 0 0
Canada
State/province [57] 0 0
Charlottetown
Country [58] 0 0
Canada
State/province [58] 0 0
Edmonton
Country [59] 0 0
Canada
State/province [59] 0 0
Halifax
Country [60] 0 0
Canada
State/province [60] 0 0
Hamilton
Country [61] 0 0
Canada
State/province [61] 0 0
Montreal
Country [62] 0 0
Canada
State/province [62] 0 0
Ottawa
Country [63] 0 0
Canada
State/province [63] 0 0
Quebec City
Country [64] 0 0
Canada
State/province [64] 0 0
Saskatoon
Country [65] 0 0
Canada
State/province [65] 0 0
Vancouver
Country [66] 0 0
Canada
State/province [66] 0 0
Victoria
Country [67] 0 0
Canada
State/province [67] 0 0
Windsor
Country [68] 0 0
Canada
State/province [68] 0 0
Winnipeg
Country [69] 0 0
Chile
State/province [69] 0 0
Independencia
Country [70] 0 0
Chile
State/province [70] 0 0
Puente Alto
Country [71] 0 0
Chile
State/province [71] 0 0
Quinta Normal
Country [72] 0 0
Chile
State/province [72] 0 0
Santiago
Country [73] 0 0
Czech Republic
State/province [73] 0 0
Ceske Budejovice
Country [74] 0 0
Czech Republic
State/province [74] 0 0
Hradec Kralove
Country [75] 0 0
Czech Republic
State/province [75] 0 0
Most
Country [76] 0 0
Czech Republic
State/province [76] 0 0
Olomouc
Country [77] 0 0
Czech Republic
State/province [77] 0 0
Ostrava
Country [78] 0 0
Czech Republic
State/province [78] 0 0
Plzen-Bory
Country [79] 0 0
Czech Republic
State/province [79] 0 0
Plzen-Lochotin
Country [80] 0 0
Czech Republic
State/province [80] 0 0
Praha 2
Country [81] 0 0
Czech Republic
State/province [81] 0 0
Praha 4
Country [82] 0 0
Czech Republic
State/province [82] 0 0
Praha 5
Country [83] 0 0
Czech Republic
State/province [83] 0 0
Zlin
Country [84] 0 0
Denmark
State/province [84] 0 0
Herning
Country [85] 0 0
Denmark
State/province [85] 0 0
Hillerod
Country [86] 0 0
Denmark
State/province [86] 0 0
Hvidovre
Country [87] 0 0
Denmark
State/province [87] 0 0
Viborg
Country [88] 0 0
France
State/province [88] 0 0
Amiens Cedex 1
Country [89] 0 0
France
State/province [89] 0 0
Angers
Country [90] 0 0
France
State/province [90] 0 0
Besancon
Country [91] 0 0
France
State/province [91] 0 0
Bordeaux
Country [92] 0 0
France
State/province [92] 0 0
Chambery
Country [93] 0 0
France
State/province [93] 0 0
Dijon
Country [94] 0 0
France
State/province [94] 0 0
Lille
Country [95] 0 0
France
State/province [95] 0 0
Marseille
Country [96] 0 0
France
State/province [96] 0 0
Montpellier
Country [97] 0 0
France
State/province [97] 0 0
Nantes
Country [98] 0 0
France
State/province [98] 0 0
Poissy Cedex
Country [99] 0 0
France
State/province [99] 0 0
Rennes Cedex
Country [100] 0 0
France
State/province [100] 0 0
Rouen Cedex
Country [101] 0 0
France
State/province [101] 0 0
Strasbourg
Country [102] 0 0
France
State/province [102] 0 0
Toulouse Cedex 9
Country [103] 0 0
France
State/province [103] 0 0
Tours Cedex
Country [104] 0 0
Germany
State/province [104] 0 0
Bochum
Country [105] 0 0
Germany
State/province [105] 0 0
Duisburg
Country [106] 0 0
Germany
State/province [106] 0 0
Dusseldorf
Country [107] 0 0
Germany
State/province [107] 0 0
Erlangen
Country [108] 0 0
Germany
State/province [108] 0 0
Freiburg
Country [109] 0 0
Germany
State/province [109] 0 0
Gottingen
Country [110] 0 0
Germany
State/province [110] 0 0
Halle
Country [111] 0 0
Germany
State/province [111] 0 0
Hannover
Country [112] 0 0
Germany
State/province [112] 0 0
Heidelberg
Country [113] 0 0
Germany
State/province [113] 0 0
Leipzig
Country [114] 0 0
Germany
State/province [114] 0 0
Mainz
Country [115] 0 0
Germany
State/province [115] 0 0
Muenchen
Country [116] 0 0
Germany
State/province [116] 0 0
Munchen
Country [117] 0 0
Germany
State/province [117] 0 0
Oberhausen
Country [118] 0 0
Germany
State/province [118] 0 0
Oldenberg
Country [119] 0 0
Germany
State/province [119] 0 0
Rosenheim
Country [120] 0 0
Germany
State/province [120] 0 0
Sankt Augustin
Country [121] 0 0
Greece
State/province [121] 0 0
Athens
Country [122] 0 0
Greece
State/province [122] 0 0
Thessaloniki
Country [123] 0 0
Hungary
State/province [123] 0 0
Budapest
Country [124] 0 0
Hungary
State/province [124] 0 0
Debrecen
Country [125] 0 0
Hungary
State/province [125] 0 0
Gyor
Country [126] 0 0
Hungary
State/province [126] 0 0
Miskolc
Country [127] 0 0
Hungary
State/province [127] 0 0
Nyiregyhaza
Country [128] 0 0
Hungary
State/province [128] 0 0
Pecs
Country [129] 0 0
Hungary
State/province [129] 0 0
Veszprem
Country [130] 0 0
Iceland
State/province [130] 0 0
Reykjavik
Country [131] 0 0
Israel
State/province [131] 0 0
Afula
Country [132] 0 0
Israel
State/province [132] 0 0
Ashkelon
Country [133] 0 0
Israel
State/province [133] 0 0
Beer-Sheva
Country [134] 0 0
Israel
State/province [134] 0 0
Haifa
Country [135] 0 0
Israel
State/province [135] 0 0
Holon
Country [136] 0 0
Israel
State/province [136] 0 0
Jerusalem
Country [137] 0 0
Israel
State/province [137] 0 0
Kfar-Saba
Country [138] 0 0
Israel
State/province [138] 0 0
Natanya
Country [139] 0 0
Israel
State/province [139] 0 0
Petach Tikva
Country [140] 0 0
Israel
State/province [140] 0 0
Rehovot
Country [141] 0 0
Israel
State/province [141] 0 0
Tel-Aviv
Country [142] 0 0
Israel
State/province [142] 0 0
Tel-Hashomer
Country [143] 0 0
Israel
State/province [143] 0 0
Tiberia
Country [144] 0 0
Italy
State/province [144] 0 0
Ancona
Country [145] 0 0
Italy
State/province [145] 0 0
Bergamo
Country [146] 0 0
Italy
State/province [146] 0 0
Bologna
Country [147] 0 0
Italy
State/province [147] 0 0
Bolzano
Country [148] 0 0
Italy
State/province [148] 0 0
Brescia
Country [149] 0 0
Italy
State/province [149] 0 0
Cuneo
Country [150] 0 0
Italy
State/province [150] 0 0
Foggia
Country [151] 0 0
Italy
State/province [151] 0 0
Imola
Country [152] 0 0
Italy
State/province [152] 0 0
Lecco
Country [153] 0 0
Italy
State/province [153] 0 0
Messina
Country [154] 0 0
Italy
State/province [154] 0 0
Monza
Country [155] 0 0
Italy
State/province [155] 0 0
Parma
Country [156] 0 0
Italy
State/province [156] 0 0
Pisa
Country [157] 0 0
Italy
State/province [157] 0 0
Torino
Country [158] 0 0
Italy
State/province [158] 0 0
Udine
Country [159] 0 0
New Zealand
State/province [159] 0 0
Auckland
Country [160] 0 0
New Zealand
State/province [160] 0 0
Dunedin
Country [161] 0 0
New Zealand
State/province [161] 0 0
Hamilton
Country [162] 0 0
New Zealand
State/province [162] 0 0
Palmerston North
Country [163] 0 0
Poland
State/province [163] 0 0
Bialystok
Country [164] 0 0
Poland
State/province [164] 0 0
Bydgoszcz
Country [165] 0 0
Poland
State/province [165] 0 0
Czestochowa
Country [166] 0 0
Poland
State/province [166] 0 0
Gdansk
Country [167] 0 0
Poland
State/province [167] 0 0
Gdynia
Country [168] 0 0
Poland
State/province [168] 0 0
Krakow
Country [169] 0 0
Poland
State/province [169] 0 0
Leczna
Country [170] 0 0
Poland
State/province [170] 0 0
Lublin
Country [171] 0 0
Poland
State/province [171] 0 0
Poznan
Country [172] 0 0
Poland
State/province [172] 0 0
Szczecin
Country [173] 0 0
Poland
State/province [173] 0 0
Warsaw
Country [174] 0 0
Poland
State/province [174] 0 0
Warszawa
Country [175] 0 0
Poland
State/province [175] 0 0
Lódz
Country [176] 0 0
Russian Federation
State/province [176] 0 0
Moscow
Country [177] 0 0
Russian Federation
State/province [177] 0 0
Smolensk
Country [178] 0 0
Russian Federation
State/province [178] 0 0
St. Petersburg
Country [179] 0 0
Spain
State/province [179] 0 0
Barcelona
Country [180] 0 0
Spain
State/province [180] 0 0
Cruces
Country [181] 0 0
Spain
State/province [181] 0 0
Córdoba
Country [182] 0 0
Spain
State/province [182] 0 0
Gerona
Country [183] 0 0
Spain
State/province [183] 0 0
Granada
Country [184] 0 0
Spain
State/province [184] 0 0
Guipuzcoa
Country [185] 0 0
Spain
State/province [185] 0 0
Jaén
Country [186] 0 0
Spain
State/province [186] 0 0
Jerez
Country [187] 0 0
Spain
State/province [187] 0 0
La Coruña
Country [188] 0 0
Spain
State/province [188] 0 0
Las Palmas de Gran Canaria
Country [189] 0 0
Spain
State/province [189] 0 0
Madrid
Country [190] 0 0
Spain
State/province [190] 0 0
Malaga
Country [191] 0 0
Spain
State/province [191] 0 0
Oviedo
Country [192] 0 0
Spain
State/province [192] 0 0
Salamanca
Country [193] 0 0
Spain
State/province [193] 0 0
Santa Cruz de Tenerife
Country [194] 0 0
Spain
State/province [194] 0 0
Santiago de Compostela
Country [195] 0 0
Spain
State/province [195] 0 0
Sevilla
Country [196] 0 0
Spain
State/province [196] 0 0
Tarragona
Country [197] 0 0
Spain
State/province [197] 0 0
Valencia
Country [198] 0 0
Spain
State/province [198] 0 0
Vigo
Country [199] 0 0
Sweden
State/province [199] 0 0
Eskilstuna
Country [200] 0 0
Sweden
State/province [200] 0 0
Goteborg
Country [201] 0 0
Sweden
State/province [201] 0 0
Stockholm
Country [202] 0 0
Sweden
State/province [202] 0 0
Uppsala
Country [203] 0 0
Turkey
State/province [203] 0 0
Ankara
Country [204] 0 0
Turkey
State/province [204] 0 0
Izmir
Country [205] 0 0
United Kingdom
State/province [205] 0 0
Birmingham
Country [206] 0 0
United Kingdom
State/province [206] 0 0
Dumfries
Country [207] 0 0
United Kingdom
State/province [207] 0 0
Dundee
Country [208] 0 0
United Kingdom
State/province [208] 0 0
Gillingham Kent
Country [209] 0 0
United Kingdom
State/province [209] 0 0
Hants
Country [210] 0 0
United Kingdom
State/province [210] 0 0
Leeds
Country [211] 0 0
United Kingdom
State/province [211] 0 0
Middlesborough
Country [212] 0 0
United Kingdom
State/province [212] 0 0
Nottingham
Country [213] 0 0
United Kingdom
State/province [213] 0 0
Sheffield
Country [214] 0 0
United Kingdom
State/province [214] 0 0
Winchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
MedImmune LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study was to compare the safety and efficacy of motavizumab to
palivizumab when administered monthly by intramuscular (IM) injection for the reduction of
the incidence of RSV hospitalization among children at high risk for serious RSV disease. A
secondary objective was to compare the incidence of medically-attended lower respiratory
infections (LRIs) between treatment groups.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00129766
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
M Pamela Griffin, MD
Address 0 0
MedImmune LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00129766